Jinyi Capital
VC Fund
Beijing, China
Jinyi Capital is an investment firm that provides asset management, investment management and consulting services.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Jinyi Capital invests in
Stages Jinyi Capital invests in
Countries Jinyi Capital invests in
Investment Focus
Industry
- Health Care 5 (33%)
- Biotechnology 3 (20%)
- Artificial Intelligence 3 (20%)
- Cosmetics 2 (13%)
- Manufacturing 2 (13%)
Stage
- Series B 4 (27%)
- Seed 2 (13%)
- Series C 2 (13%)
- Series D 2 (13%)
- Series A 1 (7%)
Country
- China 11 (73%)
- Singapore 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Deep Intelligent Pharma
|
Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche. | $40M / Venture - Series Unknown / Mar 04, 2026 | |
|
Deep Intelligent Pharma
|
Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche. | $60M / Series D / Feb 02, 2026 | |
Leapmotor
|
Zhejiang Zero Run Technology Co., Ltd. (LEAPMOTOR) is an innovative intelligent electric vehicle enterprise jointly invested by Zhejiang Dahua Technology Co., Ltd. and its main founders. Founded in 2015, the company is headquartered in Hangzhou Binjiang High-tech Development Zone. The company's business scope covers intelligent electricvehicle design, R&D, intelligent driving, motor electronic control, battery system development, and cloud computing-based car networking solutions. Relying on the strong financial strength of Dahua and its mature experience in technology research and development, process system and quality management, the company emphasizes the culture of engineers and has the ultimate pursuit of technological innovation, industrial design, and process quality. | $428.2M / Post-IPO Equity / Jan 07, 2026 | |
Shanghai Auntie
|
Shanghai Auntie is a tea company dedicated to providing young people with healthy, delicious, and affordable Wugu tea. | $103K / Aug 13, 2023 | |
|
Shanghai Auntie
|
Shanghai Auntie is a tea company dedicated to providing young people with healthy, delicious, and affordable Wugu tea. | $101.4K / Series B / Aug 13, 2023 | |
Artivila Therapeutics
|
Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform,providing first-in-class new molecules consistently and efficiently.Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China. | $15.8M / Seed / Mar 31, 2022 | |
Metanovas Biotech
|
Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M / Seed / Mar 30, 2022 | |
Lito Medical
|
Lito Medical is a comprehensive dental product and service provider. | $60M / Series A / Mar 02, 2022 | |
Abogen Biosciences
|
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases. | $300M / Series C / Nov 29, 2021 | |
Gaussian Robot
|
Gaussian Robot is a developer of commercial automatic sweeping robots. It is mainly engaged in automatic commercial products such as automatic navigation vans, automatic commercial sweepers and service robots. Shanghai Gaoxian Automation Technology Development Co., Ltd. products. | $187.8M / Series C / Nov 10, 2021 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jinyi Capital invest in?
Jinyi Capital invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Series B and Seed stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jinyi Capital last invest?
The most recent investment recorded for Jinyi Capital closed in Mar 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
